GENEVA/LONDON — Two studies showing how scientists mutated the H5N1 bird flu virus into a form that could cause a deadly human pandemic will be published only after experts fully assess the risks, the World Health Organisation (WHO) said on Friday.
Speaking after a high-level meeting of flu experts and US security officials in Geneva, a WHO official said an deal had been reached in principle to keep details of the controversial work secret until deeper risk analyses could be carried out.
“There is a preference from a public health perspective for full disclosure of the information in these two studies. However, there are significant public concerns surrounding this research that should first be addressed,” said Keiji Fukuda, the WHO’s assistant director-general for health security and environment.
WHO called the meeting to break a deadlock between scientists who have studied the mutations needed to make H5N1 bird flu transmit between mammals and the US National Science Advisory Board for Biosecurity (NSABB), which wanted the work censored before it was published in scientific journals.
Biosecurity experts fear mutated forms of the virus that research teams in The Netherlands and the United States independently created could escape or fall into the wrong hands and be used to spark a pandemic worse than the 1918-19 outbreak of Spanish flu that killed up to 40 million people.
WHO spokesman Gregory Hartl said that because of these fears, “there must be a much fuller discussion of risk and benefits of research in this area and risks of virus itself”.
But a scientist close to the NSABB who spoke to Reuters immediately after the decision said the board was deeply “frustrated” by the situation.
The only NSABB member attending the meeting was infectious disease expert Paul Keim of Northern Arizona University.
“It was a closed meeting dominated by flu people who have a vested interest in continuing this kind of work,” he added.
The WHO said experts at the meeting included lead researchers of the two studies, scientific journals interested in publishing the research, funders of the research, countries who provided the viruses, bioethicists and directors from several WHO-linked laboratories specialising in influenza.
High fatality rate
The H5N1 virus, first detected in Hong Kong in 1997, is entrenched among poultry in many countries, mainly in Asia, but so far remains in a form that is hard for humans to catch.
It is known to have infected nearly 600 people worldwide since 2003, killing half of them, a far higher death rate than the H1N1 swine flu which caused a flu pandemic in 2009/2010.
Last year, two teams of scientists – one led by Ron Fouchier at Erasmus Medical Centre and another led by Yoshihiro Kawaoka at the University of Wisconsin – said they had found that just a handful of mutations would allow H5N1 to spread like ordinary flu between mammals, and remain as deadly as it is now.
This type of research is seen as vital for scientists working to develop vaccines, diagnostic tests and anti-viral drugs that could be deployed in the event of an H5N1 pandemic.
In December, NSABB asked two leading scientific journals, Nature and Science, to withhold details of the research for fear it could be used by bioterrorists.
They said a potentially deadlier form of bird flu poses one of the gravest known threats to the human population and justified the unprecedented call to censor the research.
WHO voiced concerns, and flu researchers from around the world declared a 60-day moratorium on January 20 on “any research involving highly pathogenic avian influenza H5N1 viruses” that produce easily contagious forms.
In its current form, people can contract H5N1 only through close contact with ducks, chickens or other birds that carry it, and not from infected individuals.
But H5N1 can acquire mutations that allow it to live in the upper respiratory tract rather than the lower, and the Dutch and US researchers found a way to make it travel via airborne droplets between infected ferrets. Flu viruses are thought to behave similarly in the animals and in people.
Asked about the potential bioterrorism risks of his and the US team’s work, Fouchier said “it was the view of the entire group” at the meeting that the risks that this particular virus or flu viruses in general could be used as bioterrorism agents “would be very, very slim”.